

The Big Picture: The current and evolving HIV prevention landscape

Daisy Ouya (AVAC)

MATRIX Stakeholders Consultation

Nairobi, Kenya

November 2022



The HIV landscape globally and in SSA


- 38.4 million people living with HIV in 2021
- 36.7 million are 15 years +
- 54% of these are women and girls
- Every week, around 4,900 young women aged 15–24 years are infected with HIV

In sub-Saharan Africa

- 6 in 7 new HIV infections among adolescents aged 15–19 years are among girls.
- Young women and girls aged 15–24 years are twice as likely to be living with HIV than young men.
- Women and girls accounted for 63% of all new HIV infections in 2021

The HIV landscape in Kenya

- 32,027 new infections in 2021
- 4.5% prevalence in 2020




What biomedical tools do we have?



What biomedical tools do we have?



Global Oral PrEP Landscape – 11 years in



Source: AVAC Global PrEP Tracker, Q2 2022, <https://www.prepwatch.org/country-updates/>

PrEP continuation rates decline significantly after 3 months of use – across all populations. Daily pill taking isn't for everyone.

Target by 2020



3 million people with access to PrEP

Actual total initiations thru Q2 2022 (approx.): 2.8 million

What biomedical tools do we have?



Access to the Dapivirine Vaginal Ring: A timeline on progress

2020

Jul 2020
The **EMA** issues a positive opinion for the ring's use by women 18 yrs and older, in developing countries.

2021

March 2021
PEPFAR includes the ring in COP guidance for 2021.

Jul 2021
Kenya
Zimbabwe regulatory authorities approve the ring.

2022

March 2022
South Africa regulatory authorities approve the ring.

April 2022
Uganda
Zambia regulatory authorities approve the ring.


Jan 2021
WHO recommends the ring as an additional prevention choice for women at substantial risk of HIV.

Mar 2021
WHO adds the ring to clinical guidelines for ARV drugs for HIV prevention.

May 2022
eSwatini
Lesotho applying to import the ring.

Anticipated
Decisions on applications to approve the ring expected from:
Botswana
Namibia
Malawi
Rwanda
Tanzania*

*Preliminary rejection April 2022; IPM appeal in progress



- Scientific opinions and public health guidance
- Donor Guidance
- Regulatory approval

What biomedical tools do we have?



Cabotegravir long-acting injectable



The CATALYST Study

Catalyzing access to new prevention products to stop HIV

- Will involve implementation of an enhanced service delivery package that supports choice among PrEP products that have regulatory approval in each country, such as oral PrEP, PrEP ring and injectable cabotegravir for PrEP
- Will enroll women* at PEPFAR/USAID delivery sites in Kenya, Lesotho, South Africa, Uganda, and Zimbabwe
- To be conducted in two stages with currently approved oral PrEP and PrEP ring offered in Stage I, and the addition of injectable CAB PrEP in Stage II after approval by the regulatory authority in each country


**Inclusive of individuals assigned female at birth of any gender identity or individuals assigned male at birth who identify as women*



Years Ahead in HIV Prevention Research

Time to Market

★ Earliest time to market
 ✕ Discontinued



What's most important? It depends on who you are

Clinical Considerations

- Biologic efficacy
- Dosing/duration
- Reversibility
- Side effect profile
- Systemic/Topical

Policy & Program Considerations

- Delivery channel(s)
- Health system burden
- Product cost
- Program cost
- Provider training
- Demand creation

Personal/End-user Considerations

- Ease of use
- User preference
- User burden
- Discretion of use
- Contribution to stigma

The bottom line

- No one product will work for all people
- Preferences and needs change depending personal circumstances
- While some methods may be more effective than others, no method can be effective if it's not used
- Having choice is important – because the more options that are available the more likely one will be used

Acknowledgements

This program was made possible by the generous support of the American people through the U.S. President's Emergency Plan for AIDS Relief (PEPFAR) and the U.S. Agency for International Development (USAID).

The contents in this presentation are those of the presenter and do not necessarily reflect the view of the U.S. President's Emergency Plan for AIDS Relief, the U.S. Agency for International Development or the U.S. Government.



Questions?
Comments?

Thank you